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DissolutionAbstract Two simple, accurate, precise, economical procedures, entailing neither irksome sample
treatment nor tedious extraction process have been developed for the simultaneous estimation of
rabeprazole sodium and levosulpiride in combined tablet dosage form. The ﬁrst method was based
on employing simultaneous equation method for analysis of both drugs. Rabeprazole sodium and
levosulpiride have shown absorbance maxima at 284 and 232 nm in methanol, respectively. The sec-
ond method was based on derivative spectrophotometric method involving the determination of
both the drugs at their respective zero crossing point (ZCP). The ﬁrst order derivative spectrum
was obtained in methanol and the determinations were made at 231.2 nm (ZCP of levosulpiride)
for rabeprazole sodium and 246.2 nm (ZCP of rabeprazole sodium) for levosulpiride. The linearity
was obeyed in the concentration range of 1-20 lg/ml for both drugs. The medium of dissolution was
used 900 ml of phosphate buffer pH 7.4 using a USP type 2 apparatus at a stirring rate of 100 rpm.
The drug release was evaluated by developed spectroscopic methods. The suitability of the devel-
oped method for quantitative determination of rabeprazole sodium and levosulpiride was proved
by validation.
ª 2013 Production and hosting by Elsevier B.V. on behalf of University of Bahrain.1. Introduction
Chemically, rabeprazole sodium (RAB) is 2-({[4-(3-methoxy-
propoxy)-3-methylpyridin-2-yl]methanesulﬁnyl)-1H-benzimid-
azole sodium salt (Indian Pharmacopoeia, 2010; Merck Index,
2003) (Fig. 1) is a class of antisecretary compounds that selec-
tively inhibits gastric acid secretion by inhibiting the H+ and
K+ ATPase at secretary surface of the gastric parietal cell
Figure 1 Structure of rabeprazole sodium.
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ment of gastric and duodenal ulcers and for gastro-esophageal
reﬂux disease (GERD) (Swan et al., 1999).
Levosulpiride (LEV) is a levo-enantiomer of racemic sulpir-
ide belonging to the substituted benzamide group. Chemically
it is 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-
methoxybenzamide (Fig. 2) (Merck Index, 2003). It is a typical
neuroleptic drug with sulpiride and inhibits dopaminergic D2
receptors at the trigger zone both in the central nervous system
and in the gastrointestinal tract as stated (Barbeau, 2008).
Combination of rabeprazole sodium and levosulpiride is
available in the market which is used to help to reduce such
as the amount of acid produced by the stomach and improve
gastrointestinal motility and to treat conditions such as heart-
burn, GERD and gastritis (Swan et al., 1999). Once rabepraz-
ole has left the stomach, absorption occurs within 1 h of
administration. The bioavailability is approximately 52%.
Due to low solubility, oral formulations of levosulpiride suffer
from low absorption in the gastrointestinal tract thus resulting
to lower bioavailability. Orally administered levosulpiride is
absorbed from upper portion of the small intestine (Barbeau,
2008).
Drug dissolution (or release) testing is an analytical tech-
nique used to assess release proﬁles of drugs in pharmaceutical
products, generally solid oral products such as tablets and cap-
sules (United States Pharmacopeia, 2009; Brown, 2005). This
test gains its signiﬁcance from the fact that if a drug from a
product is to produce its effect; it must be released from the
product and should generally be dissolved in the ﬂuids of the
gastrointestinal (GI) tract. Thus, a drug dissolution test may
be considered as an indicator of potential drug release and
absorption characteristics of a product in humans as well asFigure 2 Structure of levosulpiride.in animals. Therefore, a dissolution test is often considered a
surrogate for the assessment of availability of drugs in the
body, generally termed bioavailability (Siewert et al., 2003;
Swartz, 2011).
RAB is ofﬁcial in Indian Pharmacopoeia which includes
HPLC assay method. The literature reports many analytical
methods like spectrophotometry (Gunji et al., 2012; Rahman
et al., 2008), chromatography (Bharathi et al., 2009; Choudh-
ary et al., 2009), Thin layer chromatography and High perfor-
mance thin layer (Osman and Osman, 2009; Suganthi et al.,
2008) and dissolution method (Garcia et al., 2006) for estima-
tion of Rabeprazole sodium alone or in combination with
other drugs. LEV is not ofﬁcial in any pharmacopoeia. Analyt-
ical methods like spectrophotometry (Manjunath et al., 2011),
stability indicating HPLC and HPTLC (Naguib and Abdelka-
wy, 2010), and chromatography (Walash et al., 2012) for the
determination of levosulpiride alone or in combination with
other drugs have been reported.
Simultaneous estimation of RAB and LEV in combined
dosage form by UV-spectrophotometric methods (Pekamwar
et al., 2013; Bhalodia et al., 2012) and HPLC (Patel et al.,
2012; Sirisha and Ravikumar, 2012; China Raju et al., 2012;
Agarwal and Jagdigsh, 2012) has been reported in the litera-
ture. The reported UV method (Pekamwar et al., 2013) de-
scribes only direct simultaneous estimation of RAB and LEV
at mentioned wavelengths.
The authors did not consider interference in quantitation of
one drug due to absorption of other drugs at same wavelength.
Another reported method (Bhalodia et al., 2012) was absor-
bance ratio method for simultaneous spectroscopic estimation
of RAB and LEV.
In the present work, two simple UV spectrophotometric
methods for simultaneous estimation of rabeprazole sodium
and levosulpiride in combined dosage form and its application
to determination of dissolution sample were reported. These
methods were validated according to the ICH Q2 (R1) guide-
lines ICH (2005).
2. Experimental
2.1. Materials and reagents
Rabeprazole sodium and levosulpiride bulk drugs were ob-
tained from Torrent Pharma. Pvt. Ltd, Gujarat, India, as gift
samples. Methanol (AR Grade) was purchased from Merck
(India) Ltd., Mumbai, India. AR grade chemicals and distilled
water were used during experimentation. Commercial pharma-
ceutical preparation (Rabekind Plus, Mankind Pharma, New
Delhi) was procured from the local pharmacy shop, containing
20 mg of rabeprazole sodium and 75 mg of levosulpiride (ex-
tended release).
2.2. Instrumentation
A UV-Visible spectrophotometer (Shimadzu-1700, UV Probe
2.21 software) with a spectral bandwidth of 1 nm was em-
ployed for all spectroscopic measurements, using a pair of
1.0 cm matched quartz cells over the range of 200-400 nm.
The USP dissolution apparatus Electrolab TDT-08L, was used
for dissolution study. The Elico Li 614 pH analyzer was used
to determine the pH of dissolution media, deaerated by
Figure 3 Overlain zero order spectra of RAB (3 lg/ml) and LEV (12 lg/ml).
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using a thermostatic bath.
2.3. Selection of common solvent
Methanol was selected as common solvent for studying spec-
tral characteristics of the selected drugs.
2.4. Preparation of standard stock solutions
Stock standard solutions of RAB and LEV were separately
prepared by dissolving 10 mg in 100 ml volumetric ﬂask con-
taining 50 mL methanol and the volume was made up to the
mark with methanol to obtain concentrations of 100 lg/mL
each.
2.4.1. Method I: simultaneous equation method
Appropriate volume, 0.3 mL of RAB and 1.2 ml LEV stan-
dard stock solution was transferred to two separate 10 mL vol-
umetric ﬂasks and the volume was adjusted to mark with
methanol to get concentration 3 and 12 lg/mL, respectively.
The solutions were scanned separately in the UV-region i.e.
400-200 nm. From the overlain spectra (Fig. 3) two wave-
lengths, 284 nm (kmax of RAB) and 232 nm (kmax of LEV) were
selected for the formation of simultaneous equation. The A
(1%, 1 cm) was determined at both the wavelengths selected
for each drug. A set of two simultaneous equations was formed
as:
Cx ¼ ðA2ay1  A1ay2ÞðA2ay1  A1ay2Þ=ðax2ay1
 ax1ay2Þðax2ay1  ax1ay2Þ ð1Þ
Cy ¼ ðA1ax2  A2ax1ÞðA1ax2  A2ax1Þ=ðax2ay1
 ax1ay2Þðax2ay1  ax1ay2Þ ð2Þ
where,
A1 and A2 are the absorbance of sample solutions at 284
and 232 nm, respectively.ax1 and ax2 (490, 473.0) are E (1%, 1 cm) of RAB at 284.0
and 232.0 nm.
ay1 and ay2 (77.5, 560.0) are E (1%, 1 cm) of LEV at 284.0
and 232.0 nm.
Cx and Cy are concentrations of rabeprazole sodium and
levosulpiride in mg/mL in sample solution. The values of Cx
and Cy were calculated by putting the values of A1 and A2 to
solve the simultaneous Eqs. 1 and 2 (Patel and Patel, 2008).
2.4.2. Method II: derivative spectrophotometric method
Appropriate volume, 0.3 mL of RAB and 1.2 ml LEV standard
stock solutionwas transferred to two separate 10 mLvolumetric
ﬂasks and the volumewas adjusted tomarkwithmethanol to get
concentration 3 and 12 lg/mL, respectively. The solutions were
scanned separately in the UV-region i.e. 400-200 nm. The zero-
order spectrum was processed to obtain ﬁrst-derivative spec-
trum (Patel and Patel, 2008; Dave et al., 2007). The two ﬁrst
derivative spectra were overlaid which shows that RAB showed
zero crossing at 246.2 nm, while LEV showed zero crossing at
231.2 nm. The determinations were made at 231.2 nm for
RAB (ZCP of LEV) and 246.2 nm for LEV (ZCP of RAB).The
zero order and ﬁrst order overlaying spectra are presented in
Figs. 3 and 4, respectively.
2.5. Assay of tablet formulation
Twenty tablets were accurately weighed and crushed. A quan-
tity of tablet powder equivalent to 10 mg of RAB was trans-
ferred to 100 ml volumetric ﬂask and dissolved in methanol,
sonicated for 20 min and the volume was made to 100 ml with
the same solvent. The solution was ﬁltered and was further di-
luted to get a ﬁnal concentration of about 2 lg/mL RAB and
7.5 lg/mL of LEV. The response of sample solutions was mea-
sured at 232.0 and 284.0 nm for simultaneous equation method
and at 231.2 and 246.2 nm for ﬁrst derivative method in 1 cm
cell against blank. The content of RAB and LEV in tablet dos-
age form was calculated using two framed simultaneous equa-
tions and derivative method.
Figure 4 Overlain 1st derivative spectra of RAB (3 lg/ml) and LEV (12 lg/ml).
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A quantity of tablet powder equivalent to 10 mg of rabepraz-
ole was transferred to 100 ml volumetric ﬂask and dissolved in
methanol, sonicated for 20 min. and the volume was made to
up to mark with methanol. The solution was ﬁltered through
whatman ﬁlter paper No. 41. The aliquot portion of ﬁltrate
was further diluted to get a ﬁnal concentration of about
2.0 lg/ml of rabeprazole and 7.5 lg/ml of levosulpiride. The
samples were analyzed by optimized spectroscopic method
and the reported HPLC method. The results of proposed spec-
trophotometric methods were compared with the reported RP-
HPLC method (China Raju et al., 2012).2.7. Dissolution study
Dissolution testing was carried out using paddle (USP Appa-
ratus 2) at 50 rpm using 900 ml of 0.1 N HCl as dissolution
medium for 2 h. Further, the proﬁle was determined using
900 ml phosphate buffer pH 7.4 at 100 rpm for 24 h. Sampling
aliquots of 5.0 ml were withdrawn at intervals of 5, 10, 15, 30,
45, 60, 90 and 120 min and later after every two hours up to
24 h and replaced with an equal volume of the fresh medium
to maintain a constant total volume. After the end of each test
time, sample aliquots were ﬁltered, diluted with methanol and
quantiﬁed. The analysis of dissolution samples was performed
using simultaneous equation method and ﬁrst derivative spec-
trophotometric method. The proposed methods were em-
ployed to calculate the percentage release on each time of
dissolution proﬁle.3. Method validation
The method was validated according to the ICH Q2 (R1)
guidelines for validation of analytical procedures for parame-
ters like linearity, precision, accuracy, LOD, LOQ and speciﬁc-
ity for the analyte.3.1. Linearity
Aliquot portions 0.1-2.0 mL of RAB & LEV were separately
transferred into 10 mL volumetric ﬂasks. The volume was
adjusted to the mark with methanol to obtain concentrations
1-20 lg/mL of RAB and LEV. For method I, absorbance of
these solutions was measured at 284.0 nm and 232.0 nm for
RAB and LEV, respectively. For method II, the amplitudes
from the ﬁrst order spectra were recorded at 231.2 and
246.2 nm for RAB and LEV, respectively. Calibration curve
was constructed by plotting response versus concentration.
3.2. Accuracy
To ascertain the accuracy of the proposed methods, recovery
study was carried out by standard addition method at three
different levels (80%, 100% and 120%).
The % recovery by proposed method was calculated using
the formula as below.
Recovery ¼ ðA-BÞ=C 100 ð3Þ
where
A= Total amount of drug estimated (mg).
B=Amount of drug found on pre-analyzed basis (mg).
C=Amount of bulk drug added (mg).
3.3. Precision
Precision was studied to ﬁnd out intra and inter-day variations
in the test method of RAB and LEV. Calibration curves pre-
pared in medium were run in triplicates on the same day and
for three days at three different concentration levels and %
RSD (relative standard deviation) was calculated.
3.4. Limit of detection and limit of quantitation
The limit of detection (LOD) and the limit of quantiﬁcation
(LOQ) of the drug were derived by calculating the signal-to-
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following equations designated by the International Confer-
ence on Harmonization (ICH).
LOD ¼ 3:3 r=S ð4Þ
LOQ ¼ 10 r=S ð5Þ
where,
r= the standard deviation of the response and S= slope
of the calibration curve.
3.5. Speciﬁcity study
Speciﬁcity of method was checked by estimating drug in the
presence of excipients such as lactose, starch and magnesium
stearate which are mostly available in tablet formulation.
The drug-excipient samples were prepared by considering
low and high ratio of excipient in the formulation. The
drug-excipient blend was used to prepare working standard
solution of a ﬁnal concentration of about 2 lg/mL RAB
and 7.5 lg/mL of LEV. The samples were analyzed by opti-
mized spectroscopic methods and the recovery value was
calculated.
4. Results and discussion
In the present study, we tried to develop spectroscopic meth-
ods for the simultaneous estimation of RAB and LEV from
pharmaceutical dosage form. Another aspect of the study
was to check applicability of the developed spectroscopic
methods for the determination of dissolution samples. The
two simple spectroscopic methods were developed for simulta-
neous estimation of RAB and LEV from their pharmaceutical
dosage form. The developed simultaneous equation method
and ﬁrst order derivative spectroscopic method were also used
to determine the dissolution samples. The developed methods
were validated as per the ICH guidelines for different
parameters.
4.1. Optimization of spectroscopic methods
RAB and LEV were soluble in methanol and were used as sol-
vents for the spectroscopic study.Table 1 Optical characteristics and validation of proposed method
Parameters Method I
RAB
kmax 284 nm
Linearity range 1–20 lg/ml
Correlation coeﬃcient 0.9992
Slope 0.0465·
Limit of detection (lg/ml) 0.112
Limit of quantiﬁcation (lg/ml) 0.340
Precision (% RSD)
i. Intraday precision 1.10
ii. Interday precision 1.25
% Recovery 99.45
Speciﬁcity Speciﬁc4.2. Simultaneous equation method
As the overlay spectrum of RAB and LEV (Fig. 3) shows that
there was interference in quantitation of individual drug at
their kmax due to absorption of another drug at that particular
wavelength. So, the simultaneous equation method was devel-
oped for estimation of RAB and LEV from the pharmaceutical
dosage form.
4.3. First derivative spectroscopic method
Another option thought for the simultaneous estimation of
RAB and LEV which avoids interference due to other drugs
in combination (Fig. 3) and interference due to excipient was
the ﬁrst derivative spectroscopic method.
4.4. Validation of spectroscopic methods
The developed simultaneous equation method and ﬁrst deriv-
ative spectroscopic method were validated as per the ICH val-
idation guidelines.
4.5. Linearity
Linear relationship was found in the concentration range of 1–
20 lg/mL for RAB and LEV by both methods and results are
shown in (Table 1).
4.6. Precision
The results of intra-day and inter-day precision were expressed
as % RSD and it was found to be NMT 2. The results of intra
and inter day precision are shown in (Table 1).
4.7. Accuracy
The recovery studies were carried out at three levels and three
determinations were made at each levels and percentage recov-
ery was calculated. From the data obtained, it was observed
that the recovery of standard drugs RAB and LEV was accu-
rate and within the limits employing both methods. The results
are mentioned in (Table 2)..
Method II
LEV RAB LEV
232 nm 231.2 nm 246.2 nm
1–20 lg/ml 1–20 lg/ml 1–20 lg/ml
0.9981 0.9982 0.9998
0.0542· 0.0033· 0.0031·
0.136 0.081 0.319
0.413 0.24 0.968
0.48 1.03 1.37
0.52 1.16 1.53
98.34 99.21 99.23
Speciﬁc Speciﬁc Speciﬁc
Table 2 Results of accuracy study.
Drugs Label claim (mg) % Excess drug added % Recovery % RSD
Method I Method II Method I Method II
RAB 20 80 99.56 98.99 0.68 1.10
100 99.15 99.40 1.09 0.88
120 99.28 99.24 0.72 0.73
LEV 75 80 98.25 98.92 0.21 0.313
100 98.40 99.35 0.65 0.250
120 98.36 99.40 0.28 0.361
Table 3 Percent recovery of rabeprazole sodium and levosulpiride in the presence of excipients.
RAB recovery LEV recovery
% Amt found ±% RSD (n= 5) % Amt found ±% RSD (n= 5)
Excipients Amount of excipient (lg/ml) Method I Method II Method I Method II
Lactose 38.88 99.75 ± 0.81 99.91 ± 0.58 99.80 ± 0.70 101.20 ± 0.37
Lactose 50.85 99.10 ± 0.70 99.65 ± 0.85 100.10 ± 0.95 100.80 ± 0.60
Starch 1.79 100.30 ± 0.95 100.10 ± 0.45 99.90 ± 0.55 99.15 ± 0.80
Starch 14.95 99.80 ± 0.45 99.15 ± 0.30 99. 75 ± 0.35 99.65 ± 0.78
Magnesium stearate 0.15 101. 45 ± 0.85 101.25 ± 0.65 101. 15 ± 0.25 101.10 ± 0.55
Magnesium stearate 2.99 101.25 ± 0.25 100.30 ± 0.45 100. 45 ± 0.65 99.55 ± 0.30
Table 4 Application of proposed method for analysis of tablet formulation.
Drug RAB (n= 5) LEV (n= 5)
Method Method I Method II Reported method Method I Method II Reported method
Label claim 20 75
Amt found 20.09 19.89 19.89 73.81 74.73 74.30
% Amt found 100.5 99.45 99.48 98.41 99.64 99.06
% RSD 1.41 0.79 0.29 0.33 0.50 0.57
t-Value 1.0205 1.0512 – 0.2915 1.71 –
F-value 0.04155 0.1379 – 2.2367 1.2871 –
t= 2.776 (n= 5, 0.05%), F= 6.39 (n= 5).
Table 5 Dissolution parameters for rabeprazole sodium and
levosulpiride.
Dissolution parameters
Dissolution apparatus USP apparatus II (Paddle)
Dissolution medium Phosphate buﬀer pH 7.4
Volume of dissolution medium 900 ml
Speed of paddle rotation 100 rpm
Temperature 37 ± 0.5 C
Sampling time Up to 24 h
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The values for limit of detection and limit of quantitation by
both methods are mentioned in (Table 1).
4.9. Speciﬁcity study
The recovery results indicated that the proposed methods were
speciﬁc one. No interference was found from listed excipients
and recovery values were 99.l0-101.45% for method I and99.15-101.20% for method II (Table 3). The result shows no
excipient interference in drug analysis by both optimized spec-
troscopic methods.
4.10. Drug product evaluation
The marketed brand of tablet was analyzed and amount of
RAB and LEV determined by the proposed method was found
to be 100.5% for RAB and 98.41% for LEV, respectively by
simultaneous equation method and 99.45% for RAB and
99.64% for LEV by employing ﬁrst derivative spectroscopic
method (Table 4).
4.11. Comparison with the reported method
The results of developed methods were compared with the re-
ported method and expressed in terms of t value and F value
(Table 4). The calculated F value was less than the critical va-
lue 6.39 for variance at a 0.05%. The calculated t value was
also less than theoretical critical value 2.776 for the two opti-
mized spectroscopic methods. The differences between means
Figure 5 Dissolution proﬁle of rabeprazole sodium employing methods I and II.
Figure 6 Dissolution proﬁle of levosulpiride employing methods
I and II.
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ported method shows that the developed methods are accurate
and precise.
4.12. Dissolution study
The dissolution conditions were optimized after evaluating the
release using different dissolution media viz. 0.1 N HCl, pH 4.5
acetate buffer and pH 7.4 phosphate buffer. The release proﬁle
was also evaluated at different speed of paddle rotations i.e. at
50, 75 and 100 rpm. The optimized dissolution conditions are
mentioned in (Table 5). The % cumulative drug release of
RAB and LEV was evaluated by simultaneous equation meth-
od and ﬁrst derivative spectroscopic method. It was found sat-
isfactory for Rabeprazole and extended release of
Levosulpiride as shown in Figs. 5 and 6.
5. Conclusion
The most noteworthy feature of this method is its simplicity
and rapidity and non-requiring-time consuming sample prepa-
rations such as extraction of solvents, heating, and degassing
which are needed for the HPLC procedure. These are novel
methods and can be employed for routine analysis in quality
control analysis. The described methods are giving accurate
and precise results for the determination of RabeprazoleSodium and Levosulpiride mixture in marketed formulation.
The proposed methods could be satisfactorily employed in
dissolution studies to determine the percentage drug release.
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